Stockscreener 앱 받기
1.24
14.81%
0.16
시간 외 거래:
1.30
0.06
+4.84%
Zyversa Therapeutics Inc 주식(ZVSA)의 최신 뉴스
Anson Funds Management LP Acquires New Stake in ZyVersa Therapeu - GuruFocus.com
ZyVersa Therapeutics Reports Q3 Progress and Outlook - TipRanks
ZyVersa Therapeutics Inc (ZVSA) Quarterly 10-Q Report - Quartzy
ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update - GlobeNewswire
ZyVersa Plans Key Clinical Trials as Q3 Losses Narrow, Faces Cash Needs | ZVSA Stock News - StockTitan
ZVSA stock plunges to 52-week low, hitting $1.34 amid market challenges - Investing.com UK
United States shares higher at close of trade; Dow Jones Industrial Average up 3.56% - Investing.com India
ZyVersa Therapeutics, Inc. (ZVSA): A 38.8% Stock Surge Highlights Innovative Approach to Inflammatory Disease with IC 100 - BP Journal
Agrify Corporation (AGFY): Strategic Restructuring and New Leadership Boosts Stock by 33% as Green Thumb Invests $20 Million - BP Journal
Curis Inc. (CRIS) Stock Surges 5.08% Amid Strong Biotech Sector Performance - GuruFocus.com
Stock Market Movers Today • Top Gainers & Losers - Benzinga
"Trump Media (NASDAQ: DJT) Surges on Election Day as SmallCap Stocks CRDL, ALBT, ZVSA, PRSO Emerge" - openPR
Wall Street-Heavily Traded - WDRB
Dow Jumps 400 Points; Yum! Brands Posts Downbeat Earnings - Benzinga
S&P 500 Gains 1%; Vimeo Shares Spike Higher - Benzinga
Bionomics Limited (BNOX): Stock Soars Over 162% Following Milestone Payment from Carina Biotech - BP Journal
U.S. Stock market: Zoomcar Holdings (+192.21%), Avalon GloboCare (+56.73%), and Vimeo (+40.85%) experience significant gains during mid day trading - Business Upturn
ZyVersa (ZVSA) Stock Gains Momentum With Latest Research - Stocks Telegraph
U.S. Stock market: Zoomcar Holdings up 87.10%, Avalon GloboCare jumps 57.14%, Vimeo rises 44.07% among top gainers - Business Upturn
U.S. Stock market: Verrica Pharmaceuticals and Marqeta stocks plummet over 37%, while Avalon GloboCare soars 75% in volatile market trend - Business Upturn
Nasdaq Gains Over 100 Points; US Trade Deficit Widens In September - Benzinga
ZyVersa reports progress on obesity inflammation treatment By Investing.com - Investing.com South Africa
ZyVersa reports progress on obesity inflammation treatment - Investing.com India
ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes - The Manila Times
ZyVersa Therapeutics Highlights Published Data - GlobeNewswire
ZyVersa's Breakthrough: New Data Shows Promise for Type 2 Diabetes Prevention | ZVSA Stock | ZVSA Stock News - StockTitan
Why Palantir Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket - Benzinga
ZyVersa Therapeutics Highlights Review Article Supporting the Need for Drug Therapies to Treat the Inflammation of Obesity in Addition to Weight Loss Drugs - The Manila Times
ZyVersa Therapeutics Highlights Review Article Supporting - GlobeNewswire
Iterum Therapeutics (ITRM) Scores FDA Approval for New UTI Drug ORLYNVAH™ - BP Journal
ZyVersa reports obesity-linked brain inflammation study By Investing.com - Investing.com Canada
ZyVersa reports obesity-linked brain inflammation study - Investing.com
ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases - GlobeNewswire
ZVSA stock touches 52-week low at $2.07 amid sharp annual decline - Investing.com Canada
ZVSAZyVersa Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
ZyVersa advances obesity drug with key milestones ahead - Investing.com India
ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine Months - The Manila Times
ZyVersa advances obesity drug with key milestones ahead By Investing.com - Investing.com UK
ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter - GlobeNewswire
ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured - GlobeNewswire
ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to - The Bakersfield Californian
ZyVersa forms new SAB for obesity treatment advancement By Investing.com - Investing.com South Africa
ZyVersa forms new SAB for obesity treatment advancement - Investing.com India
ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic Complications - The Manila Times
ZyVersa Therapeutics Forms New Scientific Advisory Board to - GlobeNewswire
Proteinuria Therapeutics Strategic Business Report 2024: Innovations in Biomarker-Based Diagnosis Sustain Growth in Proteinuria Therapeutics MarketForecasts to 2030 - 24matins.uk
Seelos Therapeutics, Inc. (SEEL): A Strategic Move with SLS-002 in the Fight Against PTSD - BP Journal
Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket - Benzinga
Singular Genomics (OMIC) Receives Buyout Offer, Stock Soars - BP Journal
ZVSA stock touches 52-week low at $2.4 amid sharp annual decline - Investing.com UK
Instil Bio (TIL) Surges on Promising Cancer Therapy Licensing Deal - BP Journal
SINTX Technologies (SINT) Secures Key Patent, Solidifies Leadership in Advanced Ceramics - BP Journal
SPAR Group to Go Private in $2.50 Per Share Buyout by Highwire Capital - BP Journal
Thinking about buying stock in Visa Inc, Delta Air Lines, Barnes - GuruFocus.com
XORTX Therapeutics Inc ($XRTX): Pioneering New Treatments for Kidney Disease with a Precision-Medicine Approach - BP Journal
Applied DNA Sciences Inc. (NASDAQ: APDN): Expanding Horizons in DNA Technology and Clinical Testing - BP Journal
ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Short Interest Up 68.3% in July - Defense World
ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update - GlobeNewswire
3.66%
1.11%
자본화:
|
볼륨(24시간):